Nature communications · 2022
Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hosomi Koji, Saito Mayu, Park Jonguk, Murakami Haruka, Shibata Naoko, Ando Masahiro, Nagatake Takahiro, Konishi Kana, Ohno Harumi, Tanisawa Kumpei, Mohsen Attayeb, Chen Yi-An, Kawashima Hitoshi, Natsume-Kitatani Yayoi, Oka Yoshimasa, Shimizu Hidenori, Furuta Mari, Tojima Yoko, Sawane Kento, Saika Azusa, Kondo Saki, Yonejima Yasunori, Takeyama Haruko, Matsutani Akira, Mizuguchi Kenji, Miyachi Motohiko, Kunisawa Jun
Аннотация
The gut microbiome is an important determinant in various diseases. Here we perform a cross-sectional study of Japanese adults and identify the Blautia genus, especially B. wexlerae, as a commensal bacterium that is inversely correlated with obesity and type 2 diabetes mellitus. Oral administration of B. wexlerae to mice induce metabolic changes and anti-inflammatory effects that decrease both high-fat diet-induced obesity and diabetes. The beneficial effects of B. wexlerae are correlated with unique amino-acid metabolism to produce S-adenosylmethionine, acetylcholine, and L-ornithine and carbohydrate metabolism resulting in the accumulation of amylopectin and production of succinate, lactate, and acetate, with simultaneous modification of the gut bacterial composition. These findings reveal unique regulatory pathways of host and microbial metabolism that may provide novel strategies in preventive and therapeutic approaches for metabolic disorders.